I

Inventurus Knowledge Solutions Limited

IKSNSE
Market snapshot · 2026-08-11 09:39 UTC

1,746.40

+₹17.60 (+1.02%)

MARKET CAP

₹29.30K Cr

STOCK P/E

39.3x

52W HIGH

₹1,933.00

52W LOW

₹1,262.00

BOOK VALUE

₹167.36

EPS

₹44.43

ROE

SECTOR

Health Care

DEBT/EQUITY

26.87

VOLUME

1.42L

P/B RATIO

10.43x

PEG RATIO

1.41

Sector

Health Care

Themes

Health Care Equipment & SuppliesRakesh Jhunjhunwala PortfolioRekha Jhunjhunwala PortfolioTop 20 Investors in India Portfolio
E
Earnings
₹1,928.10₹1,777.90₹1,627.70₹1,477.50₹1,327.30VolumeEEEEAug '25Sep '25Nov '25Jan '26Mar '26Apr '26Jun '26Aug '26

AI Summary

✦ Clartha

Inventurus Knowledge Solutions is a technology-enabled healthcare solutions provider serving physician businesses in the United States, Canada, and Australia. Its care enablement platform supports outpatient and inpatient activities across health systems, academic medical centers, and multi-specialty and single-specialty groups. Revenue grew 19.9% year-on-year, while the TruBridge turnaround remains central to sustaining growth and improving margins. The Abridge AI stake sale for $10 million also provides capital flexibility, though it does not expand the core platform. Profit growth reached 48.4%, with improving margins indicating operating leverage, but ROE is unavailable. Debt-to-equity of 26.87 implies substantial leverage, which can amplify reported returns but increases financial risk. At 38.9x earnings, the shares appear rich relative to the reported growth profile, despite positive sentiment and 21% quarterly revenue growth. The key open question is whether TruBridge can deliver durable earnings improvement without raising execution and leverage concerns.

Valuation Metrics

Trading 8.1% above historical median. Valuation is stable — currently in the overvalued zone (z-score: +0.84). Confidence: 91%.

Live forward EPS implies next-12-month EPS of ₹68.17. Applying the stock's normalized valuation corridor produces a fair range of ₹2,355.96 to ₹2,606.82, with base value near ₹2,479.34 (+42.0% vs current price).

Forward Valuation Outlook

Live forward estimate anchored to the company's historical valuation corridor.

Below normalized range

Forward EPS

₹68.17

Forward P/E

25.6x

Base Fair Value

₹2,479.34

Fair Range

₹2,355.96 - ₹2,606.82

Upside To Base

+42.0%

Estimate Source

Live forward EPS

Growth Estimate

+27.9%

P/E
Overvalued

5Y Average

36.10

Current

39.31

Overvalued

38.24

Undervalued

34.56

P/S
Fair

5Y Average

8.04

Current

8.75

Overvalued

9.24

Undervalued

6.83

EV/EBITDA
Strongly Overvalued

5Y Average

23.18

Current

25.24

Overvalued

24.27

Undervalued

21.85

Peers & Comparison

Sector: Health Care · Theme: Health Care Equipment & Supplies

Health Care Equipment & Supplies Peers4 peers
Avg P/E: 61.4x
CompanyRev. GrowthMarginP/Evs Avg52W Perf.
CONCORD BIOTECH LIMITED
CONCORDBIOPharmaceuticals
+26.2%24.8%
49.0x
Undervalued
-20% vs avg
-17.2%
JUBILANT PHARMOVA LTD
JUBLPHARMAPharmaceuticals
+18.7%4.8%
36.7x
Undervalued
-40% vs avg
-12.7%
FORTIS HEALTHCARE LTD
FORTISHospitals & Diagnostic Centres
+17.5%11.0%
69.3x
Fair
+13% vs avg
+1.4%
LAURUS LABS LIMITED
LAURUSLABSPharmaceuticals
+29.1%15.0%
90.6x
Premium
+48% vs avg
+123.1%
WHY THESE PEERS

INVENTURUS KNOWLEDGE SO L trades at a discount (39.3x vs peer avg 61.4x), suggesting potential undervaluation relative to the Health Care Equipment & Supplies cohort. Peers include CONCORD BIOTECH LIMITED, JUBILANT PHARMOVA LTD, FORTIS HEALTHCARE LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹475 CrJun 2026

Latest net profit

₹163 CrJun 2026

Latest EPS

₹9.47Jun 2026

Net margin

46.0%Jun 2026

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %
Q1 '26Q2 '26Q3 '26Q4 '26Q1 '270.0%15.0%30.0%45.0%60.0%0.00 Cr150 Cr300 Cr450 Cr600 Cr
  • Revenue
  • Net income
  • Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share
Q1 '26Q2 '26Q3 '26Q4 '26Q1 '270.00 Cr150 Cr300 Cr450 Cr600 Cr₹0₹3₹6₹9₹12
  • Revenue
  • EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore
RevenueExpensesDepreciationOtheradjustmentsOperatingprofitOther incomeInterestOtheradjustmentsProfitbefore taxTax & otherNet Profit0.00 Cr150 Cr300 Cr450 Cr600 Cr

Latest reported period: Jun 2026

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore
Annual view
Mar 2022Mar 2023Mar 2024Mar 2025Mar 20260.00 Cr550 Cr1.10K Cr1.65K Cr2.20K Cr
  • Debt
  • Free cash flow
  • Cash & equivalents

Results

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales +250183201240241290319356404413475
Expenses +113123123124138161170178207201256
Operating Profit1376079116103129150178196212219
OPM %55%33%39%48%43%44%47%50%49%51%46%
Other Income +77166222211
Interest67224332344
Depreciation57777779101111
Profit before tax133537011399121142168185198206
Tax %15%20%18%18%16%17%20%18%21%15%21%
Net Profit +11343579283100113138146169163
EPS in Rs6.612.493.335.374.825.826.588.078.529.859.47
Raw PDF

All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).

Shareholding Pattern

HolderJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters +63.72%63.72%63.72%63.72%63.72%
FIIs +6.50%7.02%7.56%8.19%8.01%
DIIs +4.33%4.89%6.06%6.40%7.50%
Public +22.88%21.90%20.29%19.39%18.55%
Others2.57%2.47%2.37%2.30%2.22%
Jun 2026
Promoters +
FIIs +
DIIs +
Public +
Others

Events Timeline

Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

Aug 07, 2026PDFCompany Reports Open

Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

Aug 07, 2026PDFCompany Reports Open

Announcement under Regulation 30 (LODR)-Newspaper Publication

Aug 07, 2026PDFCompany Reports Open

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Aug 06, 2026PDFCompany Reports Open

Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Details Of The Stock Purchase Agreement For Sale Of Series A-1 Preferred Shares Held By Inventurus Knowledge Solutions, Inc. In Abridge AI Inc.

Aug 06, 2026PDFCompany Reports Open